林鄭:輝瑞口服藥及內地醫療人員最快今日抵港 社交距離措施未考慮再加辣
行政長官林鄭月娥在記者會上表示,醫管局已購入相當足夠數量的抗新冠病毒口服藥,其中默沙東(MRK.US)研發的「Molnupiravir」已全數抵港,並開始應用,而輝瑞(PFE.US)研發的「Paxlovid」首批將於今日(13日)抵港,其他批次未來兩至三個月內會陸續供應。不過由於保密協議,未能透露兩款藥物的實際訂購數量。
她指出,中央已應港府請求,分批派出內地醫療人員來港協助治療患者,首批75人將於今日抵港,另外300人亦料會於本週來港。她又稱現時沒有考慮社交距離措施再「加辣」,認爲目前措施已是過去兩年多以來最嚴格,要考慮社會及市民接受程度。
深圳由於出現疫情,今日(14日)起爲期一週在全市範圍內開展三輪全員核酸檢測。林鄭月娥稱即使當地籌備全員檢測,但深圳市政府仍會確保供港物資不受影響,兩地政府已於多個口岸設立跨境貨車司機接駁點,以減低傳播風險。
另外,醫管局行政總裁高拔?提到,已開始在指定診所處方抗新冠病毒口服藥應用治療,因此明天開始指定診所數目會由17間增至23間,籌數由目前3,000張升至最高4,300個張,高風險人士例如長者會是主要治療對象並可優先預約,初步計劃會佔約一半名額。而部分私家醫院亦正籌備將特定門診用於照顧確診患者,令病人可使用抗病毒口服藥。
政府專家顧問、中大呼吸系統科講座教授許樹昌補充指,兩款抗病毒口服藥主要針對高危人士,包括70歲以上長者、長者病患、免疫力低下及未完成接種疫苗(復必泰兩針/科興三針)人士。其中輝瑞「Paxlovid」可用於12歲以上患者,惟有肝或腎衰竭者不適合使用。而默沙東「Molnupiravir」可用於18歲以上患者,不適合懷孕及餵母乳等人士。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.